Search results for "hCA"

showing 10 items of 895 documents

Seroprevalence of SARs-CoV-2 among the staff and patients of a French cancer centre after first lockdown: the canSEROcov study

2021

Abstract Background In view of the potential gravity of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection for patients with cancer, epidemiological data are vital to assess virus circulation among patients and staff of cancer centres. We performed a prospective study to investigate seroprevalence of SARS-CoV-2 antibodies among staff and patients with cancer at a large cancer centre, at the end of the period of first national lockdown in France and to determine factors associated with the risk of SARS-CoV-2 infection. Methods After the first lockdown, all medical and non-medical staff, as well as all patients attending the medical oncology department were invited to unde…

0301 basic medicineMaleCancer ResearchSerology0302 clinical medicineHygieneSeroepidemiologic StudiesEpidemiologyMedicineProspective cohort studyChildmedia_commonOriginal ResearchAged 80 and overserodiagnosisseroprevalenceSocial distanceMiddle AgedSerologyOncology030220 oncology & carcinogenesisChild PreschoolCarrier StateFemaleFrancemedicine.symptomAdultmedicine.medical_specialtyAdolescentmedia_common.quotation_subjectHealth PersonnelSARS-COV-2Cancer Care FacilitiesAsymptomaticCOVID-19 Serological Testingstaff03 medical and health sciencesYoung AdultSeroprevalenceHumansAntibodyAgedbusiness.industryhealthcare workersCancerCOVID-19cancer centerCancer patientsmedicine.diseasePersonnel Hospital030104 developmental biologyFamily medicinebusinessEuropean Journal of Cancer
researchProduct

Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus.

2021

International audience; Background: Recent years have witnessed a considerable increase in clinical trials of new investigational agents for Fabry disease (FD). Several trials investigating different agents are currently in progress; however, lack of standardisation results in challenges to interpretation and comparison. To facilitate the standardisation of investigational programs, we have developed a common framework for future clinical trials in FD.Methods and findings: A broad consensus regarding clinical outcomes and ways to measure them was obtained via the Delphi methodology. 35 FD clinical experts from 4 continents, representing 3389 FD patients, participated in 3 rounds of Delphi p…

0301 basic medicineMaleDelphi TechniqueEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]Delphi methodDisease030105 genetics & heredityKidneyBiochemistry0302 clinical medicineEndocrinologyClinical outcomesClinical Trials as TopicGlobosidesTrihexosylceramidesMiddle Aged3. Good healthClinical trialIsoenzymesTreatment OutcomeInclusion and exclusion criteriaSecondary Outcome MeasureFemaleAdultmedicine.medical_specialtyConsensusLysosomal storage disorders03 medical and health sciencesQuality of life (healthcare)Inherited metabolic disordersGeneticsmedicineHumansEnzyme Replacement TherapyIntensive care medicineMolecular BiologyFabry diseaseSphingolipidsbusiness.industryClinical study designmedicine.diseaseFabry diseaseClinical trialDelphi consensusalpha-GalactosidaseQuality of LifeFabry DiseaseGlycolipidsbusiness030217 neurology & neurosurgeryMolecular genetics and metabolism
researchProduct

Predictors of Hepatitis B Surface Antigen Titers two decades after vaccination in a cohort of students and post-graduates of the Medical School at th…

2017

Introduction and objective. The introduction of a vaccine against hepatitis B virus (HBV) for newborn babies in Italy in 1991, extended to 12-year-old children for the first 12 years of application, has been a major achievement in terms of the prevention of HBV infection. The objective of this study was to analyse the long-term immunogenicity and effectiveness of HBV vaccination among healthcare students with different working seniorities. Materials and method. A cross-sectional observational study of undergraduate and postgraduate students attending the Medical School of the University of Palermo was conducted from January 2014 – July 2016. HBV serum markers were performed with commercial …

0301 basic medicineMaleHBsAgSettore MED/07 - Microbiologia E Microbiologia ClinicaStudents Medicalmedicine.disease_causeLogistic regressionCohort Studies0302 clinical medicine030212 general & internal medicineChildWaste Management and DisposalHBV infectionlcsh:Environmental sciencesSchools Medicallcsh:GE1-350Anti-HBs titreHepatitis BVaccinationCohortFemaleAdultmedicine.medical_specialtyHepatitis B virusAdolescent030106 microbiologyHBV infection HBV vaccination Anti-HBs titre Healthcare students postgraduate medical studentsHealthcare studentslcsh:Agriculture03 medical and health sciencesYoung AdultInternal medicinemedicineHumansHepatitis B VaccinesHepatitis B AntibodiesStudentsEcology Evolution Behavior and SystematicsHBV vaccinationHepatitis B virusHepatitis B Surface Antigensbusiness.industrySettore MED/44 - Medicina Del Lavorolcsh:SPublic Health Environmental and Occupational HealthOdds ratioConfidence intervalpostgraduate medical studentsCross-Sectional StudiesImmunologyObservational studybusinessBiomarkersFollow-Up Studies
researchProduct

Myeloid Cells Restrict MCMV and Drive Stress- Induced Extramedullary Hematopoiesis through STAT1

2019

Cytomegalovirus (CMV) has a high prevalence worldwide, is often fatal for immunocompromised patients, and causes bone marrow suppression. Deficiency of signal transducer and activator of transcription 1 (STAT1) results in severely impaired antiviral immunity. We have used cell- type restricted deletion of Stat1 to determine the importance of myeloid cell activity for the defense against murine CMV (MCMV). We show that myeloid STAT1 limits MCMV burden and infection- associated pathology in the spleen but does not affect ultimate clearance of infection. Unexpectedly, we found an essential role of myeloid STAT1 in the induction of extramedullary hematopoiesis (EMH). The EMH- promoting function…

0301 basic medicineMaleMuromegalovirusMyeloidIFN-II receptorReceptor Interferon alpha-betamonocytes signal transducer and activator of transcription Herpesviridae IFN-I receptor IFN-II receptor L-27 receptor TLR9 agonistmedicine.disease_causeVirus Replication0302 clinical medicineTLR9 agonistMyeloid CellsSTAT1Cells CulturedHerpesviridaeReceptors Interferonsignal transducer and activator of transcriptionvirus diseasesIL-27 receptorHerpesviridae InfectionsExtramedullary hematopoiesisKiller Cells NaturalHaematopoiesismedicine.anatomical_structureSTAT1 Transcription FactorBone marrow suppressionHematopoiesis ExtramedullaryFemalemonocytesBIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti.SpleenBiologyGeneral Biochemistry Genetics and Molecular BiologyHerpesviridaeArticle03 medical and health sciencesStress PhysiologicalmedicineAnimalsBIOMEDICINE AND HEALTHCARE. Basic Medical Sciences.Receptors Interleukinmedicine.diseaseMice Inbred C57BL030104 developmental biologyImmunologySTAT proteinbiology.protein030217 neurology & neurosurgeryGene DeletionSpleenIFN-I receptor
researchProduct

Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres.

2021

Abstract Objectives To our knowledge no previous study has assessed the performance of a rapid antigen diagnostic immunoassay (RAD) conducted at the point of care (POC). We evaluated the Panbio™ COVID-19 Ag Rapid Test Device for diagnosis of coronavirus 2019 disease (COVID-19) in symptomatic patients (n = 412) attending primary healthcare centres. Methods RAD was performed immediately after sampling following the manufacturer's instructions (reading at 15 min). RT-PCRs were carried out within 24 h of specimen collection. Samples displaying discordant results were processed for culture in Vero E6 cells. Presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cell cultures…

0301 basic medicineMaleRapid antigen detection test (RAD)medicine.disease_causeAmbulatory Care Facilities0302 clinical medicineNasopharynx030212 general & internal medicineChildAntigens ViralCoronavirusAged 80 and overImmunoassaymedicine.diagnostic_testGeneral MedicineMiddle AgedEarly diagnosisResearch NoteInfectious DiseasesSpecimen collectionRapid antigen testPoint-of-Care TestingCOVID-19 Nucleic Acid TestingChild PreschoolFemaleMicrobiology (medical)Adultmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)AdolescentPoint-of-care testing030106 microbiologySensitivity and SpecificityCOVID-19 Serological Testing03 medical and health sciencesYoung AdultAntigenInternal medicinemedicineHumansPoint of careAgedbusiness.industrySARS-CoV-2COVID-19InfantImmunoassayReagent Kits DiagnosticbusinessPrimary healthcare centreClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
researchProduct

Epidemiology of rare cancers and inequalities in oncologic outcomes

2019

Rare cancers epidemiology is better known compared to the other rare diseases. Thanks to the long history of the European population-based cancer registries and to the EUROCARE huge database, the burden of rare cancers has been estimated the European (EU28) population. A considerable fraction of all cancers is represented by rare cancers (24%). They are a heterogeneous group of diseases, but they share similar problems: uncertainty of diagnosis, lack of therapies, poor research opportunities, difficulties in clinical trials, lack of expertise and of centres of reference. This paper analyses the major epidemiological indicators of frequency (incidence and prevalence) and outcome (5-year surv…

0301 basic medicineMaleSettore MED/06 - Oncologia Medica0302 clinical medicineNeoplasmsEpidemiologyPrevalenceEurope ; Population-based cancer registry ; Rare cancersChildeducation.field_of_studyRelative survivalIncidence (epidemiology)IncidenceGeneral MedicineMiddle AgedSurvival RateEuropeHealthcare DisparitieOncology030220 oncology & carcinogenesisChild PreschoolFemaleHumanAdultmedicine.medical_specialtyAdolescentEurope; Population-based cancer registry; Rare cancers; Surgery; OncologyPopulationSocio-culturaleEurope Population-based cancer registry Rare cancers03 medical and health sciencesYoung AdultRare DiseasesAge DistributionRare DiseasemedicineHumansRare cancersHealthcare DisparitiesSex DistributioneducationPopulation-based cancer registrySurvival rateAgedbusiness.industryPublic healthInfant NewbornCancerRare cancerInfantmedicine.diseaseClinical trial030104 developmental biologyNeoplasmSurgerybusinessDemography
researchProduct

Influenza vaccination of healthcare workers in Italy: could mandatory vaccination be a solution to protect patients?

2019

Several studies have reported that influenza infections in healthcare workers (HCWs) can lead to nosocomial outbreaks. HCWs can potentially be infected with influenza every year, and may continue to work, encouraging the spread of the virus. Different strategies, such as informative interventions on influenza and influenza vaccination, ‘onsite’ vaccination weeks, communicative strategies through dedicated web and social media pages, and mandatory informed dissent form, were organized for HCWs working at the University Hospital of Palermo, during previous influenza seasons. However, the increased vaccination rates observed among HCWs still remain far from the 75% recommended by Public Healt…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyVaccination CoverageAttitude of Health Personnelhealth care facilities manpower and servicesHealth Personneleducation030106 microbiologyPsychological interventionMandatory ProgramsSettore MED/42 - Igiene Generale E ApplicataMicrobiologyInfectious Disease Transmission Professional-to-PatientHospitals University03 medical and health sciencesHealth careInfluenza HumanmedicineHumansNosocomial outbreakbusiness.industryPublic healthVaccinationvirus diseasesUniversity hospitalMandatory vaccinationcommunication strategies healthcare workers influenza disease perception influenza vaccination mandatory vaccinationVaccination030104 developmental biologyItalyInfluenza VaccinesFamily medicinebusinessFuture microbiology
researchProduct

The Mouse Cytomegalovirus Gene m42 Targets Surface Expression of the Protein Tyrosine Phosphatase CD45 in Infected Macrophages

2016

The receptor-like protein tyrosine phosphatase CD45 is expressed on the surface of cells of hematopoietic origin and has a pivotal role for the function of these cells in the immune response. Here we report that following infection of macrophages with mouse cytomegalovirus (MCMV) the cell surface expression of CD45 is drastically diminished. Screening of a set of MCMV deletion mutants allowed us to identify the viral gene m42 of being responsible for CD45 down-modulation. Moreover, expression of m42 independent of viral infection upon retroviral transduction of the RAW264.7 macrophage cell line led to comparable regulation of CD45 expression. In immunocompetent mice infected with an m42 del…

0301 basic medicineMuromegalovirusGenes ViralvirusesCell MembranesFluorescent Antibody TechniqueNEDD4Protein tyrosine phosphatasePathology and Laboratory MedicineBiochemistryLigasesWhite Blood CellsMice0302 clinical medicineSpectrum Analysis TechniquesUbiquitinAnimal CellsMedicine and Health SciencesBiology (General)Regulation of gene expressionStainingMice Inbred BALB CbiologyChemistryCell StainingAntigens CD45Herpesviridae InfectionsHuman cytomegalovirusFlow Cytometry3. Good healthEnzymesSpectrophotometryMedical MicrobiologyViral PathogensViruses293T cellsCell linesHuman CytomegalovirusCytophotometryCellular TypesCellular Structures and OrganellesPathogensBiological culturesBIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti.Research ArticleGene Expression Regulation ViralHerpesvirusesMCMV ; m42 ; CD45QH301-705.5Immune CellsImmunologyImmunoblottingDown-RegulationResearch and Analysis MethodsMicrobiologyGene product03 medical and health sciencesVirologyGeneticsAnimalsHumansMolecular BiologyMicrobial PathogensBlood CellsMacrophagesHEK 293 cellsBIOMEDICINE AND HEALTHCARE. Basic Medical Sciences.OrganismsBiology and Life SciencesProteinsMembrane ProteinsProtein phosphatase 2Cell BiologyRC581-607Ubiquitin LigasesMolecular biologyViral Replication030104 developmental biologyHEK293 CellsRAW 264.7 CellsViral replicationSpecimen Preparation and Treatmentbiology.proteinEnzymologyLeukocyte Common AntigensParasitologyImmunologic diseases. AllergyDNA viruses030215 immunology
researchProduct

The murine cytomegalovirus M35 protein antagonizes type I IFN induction downstream of pattern recognition receptors by targeting NF-κB mediated trans…

2017

The type I interferon (IFN) response is imperative for the establishment of the early antiviral immune response. Here we report the identification of the first type I IFN antagonist encoded by murine cytomegalovirus (MCMV) that shuts down signaling following pattern recognition receptor (PRR) sensing. Screening of an MCMV open reading frame (ORF) library identified M35 as a novel and strong negative modulator of IFNβ promoter induction following activation of both RNA and DNA cytoplasmic PRR. Additionally, M35 inhibits the proinflammatory cytokine response downstream of Toll-like receptors (TLR). Using a series of luciferase-based reporters with specific transcription factor binding sites, …

0301 basic medicineMuromegalovirusPhysiologymedicine.disease_causeBiochemistrychemistry.chemical_compoundMiceWhite Blood Cells0302 clinical medicineCell SignalingTranscription (biology)InterferonAnimal CellsImmune PhysiologyMedicine and Health SciencesMembrane Receptor SignalingBiology (General)Enzyme-Linked ImmunoassaysReceptorConnective Tissue CellsbiologyToll-Like ReceptorsPattern recognition receptorNF-kappa BImmune Receptor SignalingEnzymesThe murine cytomegalovirus M35 protein antagonizes type I IFN induction downstream of pattern recognition receptors by targeting NF-κB mediated transcription.Connective TissueReceptors Pattern RecognitionCytomegalovirus InfectionsInterferon Type ISignal transductionCellular TypesAnatomyBIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti.OxidoreductasesLuciferasemedicine.drugProtein BindingSignal TransductionResearch ArticleViral proteinQH301-705.5Immune CellsImmunologyResearch and Analysis MethodsTransfectionMicrobiology03 medical and health sciencesViral ProteinsMuromegalovirusVirologyGeneticsmedicineAnimalsImmunoassaysMolecular Biology TechniquesMolecular BiologyBlood CellsMacrophagesBIOMEDICINE AND HEALTHCARE. Basic Medical Sciences.Biology and Life SciencesProteinsNF-κBInterferon-betaCell BiologyRC581-607Fibroblastsbiology.organism_classificationMolecular biology030104 developmental biologyBiological TissuechemistryEnzymologyImmunologic TechniquesParasitologyInterferonsImmunologic diseases. AllergySpleen030215 immunology
researchProduct

Monoclonal antibodies for the treatment of non-hematological tumors: a safety review

2018

Introduction: The introduction of monoclonal antibodies (moAbs) into clinical practice revolutionized the treatment strategies in several solid tumors. These agents differ from cytotoxic chemotherapy for their mechanism of action and toxicity. By targeting specific antigens present on healthy cells and modulating immune system activity, these biological drugs are able to generate a wide spectrum of peculiar adverse events that can negatively impact on patients' quality of life. Areas covered: In this review, the main side effects associated with the use of moAbs have been described to show their incidence and current management strategies, which may drive clinicians in their daily practice.…

0301 basic medicineOncologyAdverse eventPD-L1medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentEGFRMonoclonal antibody03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Immune systemAntineoplastic Agents ImmunologicalInternal medicinePD-L1NeoplasmsPD-1medicineAnimalsHumansPharmacology (medical)Precision MedicineAdverse effectbiologybusiness.industrytarget therapymoAbsCancerAntibodies MonoclonalmoAbGeneral MedicineImmunotherapymedicine.diseaseVEGFSurvival Rate030104 developmental biologyCTLA-4HER-2030220 oncology & carcinogenesisAdverse eventsbiology.proteinQuality of LifeCTLA-4Adverse events; CTLA-4; EGFR; HER-2; immunotherapy; moAbs; PD-1; PD-L1; target therapy; VEGF; Pharmacology (medical)immunotherapybusiness
researchProduct